Both in Biotechnology
Surrozen vs X4 Pharmaceuticals
Over the past year SRZN returned +107.4% and XFOR returned −17.1%; their daily moves had a correlation of 0.24.
SRZN +107.4% XFOR −17.1%Growth of $1, one year, split-adjusted
| Metric | SRZN | XFOR |
|---|---|---|
| Price | $29.04 | $3.35 |
| Market cap | $341.3M | $332.1M |
| Today | −1.43% | −0.30% |
| 1 month | −3.2% | +18.4% |
| 6 months | −13.6% | −20.0% |
| Year to date | +28.5% | −16.3% |
| 1 year | +113.7% | −10.4% |
| Revenue growth (YoY) | +408.6% | +346.3% |
| Gross margin | 100.0% | 81.6% |
| Net margin | 640.8% | −183.5% |
| P/E (TTM) | — | — |
| Price / sales | 29.7× | 21.0× |
| Net cash | $102.0M | $131.2M |
| Dividend yield | — | — |
| Volatility (60d) | 174.0% | 66.2% |
| Short % of float | 37.0% | 9.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).